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Thissystematicreviewassessesthecurrentstatusofanti-cycliccitrullinatedpeptide(anti-CCP)andrheumatoidfactor(RF)testsin
the diagnosis and prognosis of rheumatoid arthritis (RA). We reviewed publications on tests and biomarkers for early diagnosis of
RA from English-language MEDLINE-indexed journals and non-MEDLINE-indexed sources. 85 publications were identiﬁed and
reviewed, including 68 studies from MEDLINE and 17 non-MEDLINE sources. Anti-CCP2 assays provide improved sensitivity
over anti-CCP assays and RF, but anti-CCP2 and RF assays in combination demonstrate a positive predictive value (PPV) nearing
100%, greater than the PPV of either of the tests alone. The combination also appears to be able to distinguish between patients
whose disease course is expected to be more severe and both tests are incorporated in the 2010 ACR Rheumatoid Arthritis
Classiﬁcation Criteria. While the clinical value of anti-CCP tests has been established, diﬀerences in cut-oﬀ values, sensitivities
and speciﬁcities exist between ﬁrst-, second- and third-generation tests and harmonization eﬀorts are under way. Anti-CCP and
RF are clinically valuable biomarkers for the diagnosis and prognosis of RA patients. The combination of the two biomarkers in
conjunction with other clinical measures is an important tool for the diagnosis and management of RA patients.
1.Introduction
Rheumatoid arthritis (RA), the most commonly occurring
form of inﬂammatory polyarthritis, is prevalent in approx-
imately 0.8% of adults worldwide [1]. Approximately 1.3
million adults in the United States have been diagnosed
with RA [2]. If untreated, 20%–30% of RA patients become
so severely debilitated within the ﬁrst three years following
initial diagnosis that they become permanently disabled [1].
Within the last decade, treatment options for RApatients
have improved dramatically. Treatment focus has shifted to
early intervention with aggressive treatment aimed at sup-
pressing inﬂammation and preventing further joint damage
[3]. Recent evidence indicates that early introduction of
methotrexate (MTX) therapy in undiﬀerentiated arthritis
(UA) patients seropositive for anti-CCP delays diﬀerentia-
tion to RA and retards the progression of joint destruction
[4]. However, initiation of treatment without a conﬁrmed
diagnosis of RA is inappropriate for at least half of patients
with UA [5], as therapies are potentially toxic and costly.
The shift to earlier, aggressive treatment would be
facilitated by more sensitive and speciﬁc early diagnostic
tests.However,thisremains challenginggiventhelimitations
of current diagnostic tools and intervention practices [6].
Clinicalevidence,laboratorytests,andimagingtestsareused
to diagnose patients suspected of RA [5, 7, 8]. However,
clinical examinations often fail to identify patients with early
RA due in part to heterogeneity of disease presentation and
course[5].Asystematicreviewofpublicationsevaluatingthe
performance of the ACR’s 1987 clinical criteria found the
sensitivity to early RA to be between 77% and 80%, with
speciﬁcities between 33% and 77% based on pooled data
[9]. Figure 1 summarizes the pathogenesis in RA and current
diagnostic tools in use.
ForpatientswithaconﬁrmeddiagnosisofRA,thecourse
of their disease can vary substantially. In some cases, disease
progression can be slow and the overall impact of the disease
rather mild, remaining a predominantly local condition.
However, for other patients the disease progression can be2 Autoimmune Diseases
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Figure 1: Pathogenesis in rheumatoid arthritis and current diagnostic tools in use.
quite aggressive with signiﬁcant joint erosion and systemic
impact [6, 10]. Accurate prognostic information would be
valuable in determining the appropriate treatment course for
these diﬀerent patient populations and improving patient
outcomes.
Tomeettheneedforimproveddiagnosticandprognostic
tests and algorithms, various serum biomarkers are being
assessed for the improved diagnosis and prognosis of RA,
including a wide range of autoantibodies. However, only
rheumatoid factor (RF) and anti-cyclic citrullinated peptide
(anti-CCP) have gained wide acceptance. We systematically
reviewed the literature pertaining to the diagnosis and
prognosis of RA to assess the current status of these two
autoantibodies as diagnostic and prognostic tests for RA.
2. Methods
We reviewed MEDLINE-indexed publications using search
strategies that included the keywords “rheumatoid arthritis”
and one of the following: (1) diagnos∗ OR monitor∗ OR
identif∗ OR detect∗,( 2 )b i o m a r k e r ∗ OR circulating OR
serum, and (3) guideline∗ OR practice pattern∗ OR treat-
mentpattern∗.Wealsosearchedforthekeyword“anti-CCP”
as a unique search criterion. The limits for these searches
included: Field: Title/Abstract, Limits: published between
August 2003 and March 2010, only items with abstracts,
humans, English, Spanish. A search for relevant guidelines
included the following limits: published in the last 10 years,
only items with abstracts, humans, English, Spanish. The
searches yielded 551 publications.
All 551 abstracts were reviewed in depth to identify arti-
cles evaluating the characteristics, performance, and clinical
utility of anti-CCP and RF tests for use in the diagnosis
of RA. Given the broad search criteria applied intended to
capture the largest number of relevant publications possible,
a total of 483 abstracts were excluded based on the exclusion
categories listed in Figure 2. In total, 68 MEDLINE-indexed
publications were retrieved in full text.
We also searched the “grey” literature (material that
can be referenced, but is not published in peer-reviewed,
MEDLINE-indexed medical journals) for information per-
taining to anti-CCP and RF for use in the diagnosis of RA.
We conducted a search on the Google search engine using
thekeywordsusedinMEDLINEsearches.Further,asearchof
guidelines related RA diagnosis was performed on the web-
site maintained by the National Guideline Clearinghouse.
The abstracts for the American College of Rheumatology’s
7th Annual Conference and the European League Against
Rheumatism (EULAR) Annual Congress 2008 also were
searched using keywords. Fifty-ﬁve publications relevant to
the study’s aim were selected for further review.
Primary research articles from the search of MEDLINE-
indexed articles that were included in this paper were
assessed for the quality of evidence provided using the
Oxford ratings system deﬁned by the Center for Evidence-
Based Medicine (CEBM). The Oxford ratings deﬁne ﬁve
levels of evidence, with level 1 being the highest level of
quality and level 5 the least. Level 1 research studies may
be used to support the highest grade A of clinical practice
recommendations, level 2 and 3 studies support grade BAutoimmune Diseases 3
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Figure 2: Literature retrieval strategy.
recommendations, while level 4 and level 5 studies may
support grade C and grade D recommendations, respectively
[11] (see Table 1).
3. Results
We identiﬁed 68 articles from MEDLINE pertaining to
current diagnostic guidelines and practices for RA, and
to anti-CCP and RF as diagnostic tests for RA. Non-
MEDLINE sources comprised of current practice guidelines
and conference abstracts yielded an additional 17 articles,
for a total of 85 publications reviewed for this study (see
Figure 2).
Of the MEDLINE publications, 48 were evaluated for
their quality of evidence using the Oxford ratings system’s
diagnostic criteria, one was evaluated using the Oxford
ratings system’s prognostic criteria, six were evaluated using
both the diagnostic and prognostic criteria, and 13 articles
werenonsystematicreviewarticlesforwhichtheratingswere
not applicable. Of the 54 diagnostic publications evaluated,
37 met the requirements for a level 1 quality of evidence that
couldsupportgradeArecommendations.Threepublications
met the level 2 requirements and could support grade B
recommendations, while the remaining 14 met the level 4
requirements and could support grade C recommendations.
Of the prognostic publications, four met the requirements
for level 1, two for level 2, and one for level 4. Overall,
the diagnostic studies were able to meet a very high level
of quality of evidence given the availability of the ACR RA
classiﬁcation criteria as an appropriate reference standard
and the high level of speciﬁcity of the anti-CCP tests. For
the prognostic studies, the requirement for level 1 is a
prospective cohortstudy withgood followup, a standard that
the majority of the studies were able to meet [11].
3.1. Pathology of Citrullinated Proteins and Autoantibodies
in RA. Posttranslational modiﬁcation of the amino acid
arginine to the amino acid citrulline is a naturally occur-
ring process mediated by protein-arginyl deaminase (PAD)
enzymes [12, 13] Citrullination is currently thought to be
involved in cell diﬀerentiation and programmed cell death
or apoptosis [12]. The naturally occurring targets of PAD
identiﬁed to date are important structural proteins [12], and
citrullination appears to mark these proteins for degradation
[12, 14]. Upon cell death, the citrullinated proteins are
released into the blood stream [15].
Van Venrooij and colleagues have hypothesized that
in RA, a triggering event results in the migration of
inﬂammatory cells into the joints and that activates of PAD
enzymes, stimulating apoptosis of the joint cells. For the vast
majority of individuals, the citrullinated proteins are cleared
normally; however, in the 1% of patients with a genetic
predisposition, the citrullinated proteins fail to be cleared
properly and elicit the production of autoantibodies, which
in turn initiate an inﬂammatory response [15]. A number
of species of citrullinated proteins have been identiﬁed
in inﬂamed synovial tissue in RA, including vimentin, α-
enolase and the α-a n dβ-chains of ﬁbrin [12]. To date, over
100 autoantibody species recognizing citrullinated proteins
have been identiﬁed in the sera of RA patients [16].4 Autoimmune Diseases
Table 1: Oxford Centre for Evidence-based Medicine deﬁnitions of levels of evidence. The following table summarizes the criteria that must
be satisﬁed for the ﬁve diﬀerent levels of evidence for both diagnostic and prognostic studies as well as the grading of recommendations
assessment, development, and evaluation (GRADE) that studies with a given level of evidence will support.
Level of
evidence
Grade of recom-
mendation
studies can
support
Criteria for diagnostic studies Criteria for prognostic studies
1A
(a) systematic review/meta analysis of level 1
studies or clinical decision rule applied to level
(b) multicenter studies
(b) cohort study with good reference standards
that validate the diagnostic test or clinical
decision rule in single center study
(c) speciﬁcity or sensitivity results that are so
high that they can rule in or rule out a
diagnosis
(a) systematic review/meta analysis of
inception cohort studies or clinical decision
rule that is validated in more than one
population
(b) single inception cohort studies with ≥80%
follow up of participants or clinical decision
rule that is validated in one population only
(c) case series where results apply to either all
or none of the subjects
2B
(a) systematic review/meta analysis of ≥level 2
diagnostic studies
(b) exploratory cohort study with good
reference standard or clinical decision rule
applied to a split sample
(a) systematic review/meta analysis of
retrospective cohort studies or untreated
control groups in randomized clinical trials
(RCTs)
(b) retrospective cohort study or untreated
control group from an RCT that is followed
over time
(c) outcomes research
3B
(a) systematic review/meta analysis of ≥level 3
diagnostic studies
(b) nonconsecutive study or study with
inconsistent use of reference standards
N/A
4C Case-control study or study with poor
reference standards Case series or poor quality cohort studies
5 D Expert opinion Expert opinion
(http://www.cebm.net/index.aspx?o=1025).
Source: GRADE (grading of recommendations assessment, development, and evaluation) Working Group 2007 1 (modiﬁed by the EBM Guidelines Editorial
Team).
3.2. Tests for Anticitrullinated Protein Antigens (ACPAs). We
found 38 primary research studies which evaluated tests for
ACPAs.Ofthese,18usedacohortstudydesignthatvalidated
ACPA test results within a deﬁned patient population, and
20 were case-control studies comparing ACPA results in RA
patients versus control populations. Thirty of these studies
met the standards for level 1 evidence, while eight of the
case-control studies only met the requirements for level 4
evidence.
Given the relationship between citrullinated proteins
and RA, autoantibodies recognizing citrullinated proteins
are attractive biomarkers of RA, and tests measuring these
autoantibodies have been in development for the past two
decades [17–20]. The ﬁrst of these tests, referred to as anti-
perinuclear factor (APF) and antikeratin antibodies (AKA),
was found to measure antibodies in the sera of RA patients
which recognized the citrullinated protein ﬁlaggrin [17–20].
While not physiologically relevant given that citrullinated
ﬁlligrin is not produced in synovial joints, these tests proved
useful nonetheless in the identiﬁcation of RA patients [12,
19]. In an eﬀort to improve test performance, Schellekens et
al. developed synthetic linear peptides based on ﬁlaggrin to
be used as the antigen in serum RA tests [17, 21].
Antibody recognition wasfurtherimproved by the devel-
opment of cyclic peptides rendering the citrulline moiety
more available to serum antibodies; these tests were referred
to as anti-cyclical citrullinated protein tests or anti-CCP
tests [17, 21]. Second- and third-generation anti-CCP tests
use combinations of synthetic cyclic citrullinated peptides
selected through a screening process to increase sensitivity
over anti-CCP1 while continuing to maintain speciﬁcity
[17, 22]. Table 2 provides a summary of ﬁrst-, second-, and
third- generation anti-CCP tests identiﬁed in this literature
review.
Recently, Pruijn and colleagues compared published
sensitivities of anti-CCP2, anti-CCP3, and anti-MCV tests
in comparative studies using the same speciﬁcity values for
the three biomarkers. The sensitivities of the anti-CCP2 tests
were equal to or better than those of the anti-CCP3 and anti-
MCV tests across all studies [24, 35, 56, 59–64].
A number of tests have been developed that measure the
presence of serum antibodies recognizing speciﬁc citrulli-
nated proteins for use as biomarkers of RA. In particular,
autoantibodies against vimentin (referred to as anti-MCV
and anti-SA) and α-enolase have attracted interest for
applications in RA testing [23, 45, 65–72]. Assays for RA
are also being developed recognizing antibodies againstAutoimmune Diseases 5
Table 2: Anti-CCP tests.
Manufacturer/test type Test∗ Cut point (U/mL) Sensitivity (%) Speciﬁcity (%) References
Abbott Laboratories Anti-CCP 5 69.4 97.6 [23]
AxSYM 5 80.6 84.3 [24]
Anti-CCP2
Axis-Shield Diagnostics
Anti-CCP 7.2 52.8 100 [25]
Anti-CCP2
4.5 82.4 82.8 [26]
4.6 83.3 93 [27]
5 53.7–67.5 90.4–99.3 [28–31]
5.6 88 81 [32]
25 71 65 [10]
Eurodiagnostica
Anti-CCP
20.7 52.8 100 [25]
53 47 94 [33]
65 43.8 98.4 [34]
Anti-CCP2
5 66.7 97 [29]
25 66.7–76.5 92.2–97.3 [29, 35–37]
42 73.7 98.6 [36]
Euroimmun
Anti-CCP
5 39.2–65 95.2–99 [38–41]
14.8 81.6 87.5 [42]
25 56 96 [43]
Anti-CCP2 5 66.7–72.5 96.4–97.7 [29, 35]
5.25 78.7 95.6 [44]
Fuchun-Zhongnan Biotech Anti-CCP2 25 61.8 96.3 [45]
Genesis Anti-CCP2 6.25 69.6 93.9 [35]
Immunoscan Anti-CCP2 25 54–64.4 96–97.1 [46, 47]
In-house ELISA test Anti-CCP1 92 42 97 [47]
INOVA Diagnostics
Anti-CCP 6.4 58.5 100 [25]
Anti-CCP2
20 60.2–78.6 70.3–98.8 [22, 24, 29, 35, 48–52]
25 82 96 [53]
30 70 91.5 [54]
Anti-CCP3 20 61.3–82.9 93–97.6 [24, 29, 49, 51]
MBL Co. Anti-CCP 3.8 72.8 92 [55]
Phadia GmbH Anti-CCP2 7 77.5 95.9 [35]
10 70.1 98.7 [56]
Pharmacia Diagnostica Anti-CCP2 7 80.3 97 [22]
Roche Diagnostics Anti-CCP2
96 9 9 3[ 57]
13.6 92.2 86.2 [58]
17 90.6 86.8 [58]
∗The generation of anti-CCP test indicated is as reported in the methods section of the articles referenced.
modiﬁed citrullinated peptides, like chimeric ﬁbrin/ﬁlaggrin
[73].
3.3. Harmonization of Anti-CCP Tests. Given that all three
generations of anti-CCP tests as well as other ACPA tests are
currently available commercially, there has been a growing
recognition that the results of these tests are not consistent
acrossdiﬀerentlaboratoriesandthatharmonizationofACPA
test results is needed [35, 63, 74]. Several authors have
discussed important diﬃculties in comparing test results
across ACPA tests including diﬀerences in cutoﬀ values, the
need for a common reference material, and the need to
includenoncitrullinatedantigensinACPAteststocontrolfor
nonspeciﬁc binding of ACPAs to arginine residues [35, 63,
74–76]. Table 2 underscores the need for harmonization of
anti-CCPtests,illustratingthehugevariationincutoﬀvalues
and performance characteristics of ﬁrst-, second-, and third-
generation anti-CCP tests.
Among current eﬀorts at harmonization of ACPA tests
are the development of international reference reagents by
the Centers for Disease Control and Prevention [63]a n d
theIUISAutoantibodyStandardizationCommittee[74],and
the establishment of a bank of sera from patients with RA
and other rheumatic diseases by the European AutoCure
consortium for use in diagnostic test comparisons [63].
3.4. Anti-CCP as a Predictive Tool for RA. We identiﬁed
six primary research articles that assessed anti-CCP tests as6 Autoimmune Diseases
predictive tools for RA. Of these, three were cohort studies,
two were case-control studies, and one was a systematic
review of the anti-CCP literature. Four studies met the
criteriaforlevel1evidence,onemetthelevel2requirements,
and one met the criteria for level 4 evidence.
Anti-CCP is present in the serum of a portion of RA
patients and has been identiﬁed in the serum of patients at
all stages of RA: preclinical, early, and established. In clinical
research studies, anti-CCP antibodies were found in 55%–
69% of patients with RA, [65, 77] 65% of RA patients with
late-onset RA [78], and 10% of patients with juvenile-onset
arthritis [77]. Blood bank studies have identiﬁed anti-CCP
antibodies in the serum of patients as many as 12 to 14 years
prior to the development of RA [79–82]. In these studies,
34%–40% of the RA patients had anti-CCP+ results prior
to disease onset [79–82]. The length of time that anti-CCP
antibodies are detectable in patient serum prior to disease
onsetappearstobeagerelated. Serumanti-CCP isdetectable
in the serum of older patients well before the developmental
ofclinicalsymptoms,whileinyoungerpatients,thedetection
of serum anti-CCP occurs closer to the time of disease onset
[83].
In patients with UA, anti-CCP+ serum can indicate
patient risk of developing RA [27]. One study of UA patients
with anti-CCP2+ serum reported an odds ratio (OR) of
25 [12, 84]. The diﬀerence between patients who produce
anti-CCP antibodies and those who do not may be partly
genetic. A study of UA patients who were later diagnosed
with RA found an important association between anti-CCP
and the shared epitope (SE) genetic predisposition [85]. The
presence of anti-CCP has been associated with HLA-DRB1
alleles known to carry SE [17, 86, 87]. SE has also been
shown to be associated with the production of antibodies
against a range of citrullinated proteins found in inﬂamed
synovial tissue, including vimentin and α-enolase [65]. The
combination of anti-CCP+ serum and a class II MHC allele
with SE appears to be associated with an increased patient
risk of developing RA, as evidenced by a reported OR of 66.8
for patients with the combination versus an OR of 25.1 for
patients with anti-CCP+ serum only [17, 88].
3.5. Anti-CCP as a Diagnostic Tool for RA. We identiﬁed
37 primary research studies that evaluated anti-CCP tests
of which 18 used a cohort study design that validated anti-
CCP tests for use as diagnostic tools within a deﬁned patient
population and 19 were case-control studies comparing
anti-CCP results in RA patients versus control populations.
Twenty-eight of these studies met the standards for level 1
evidence, while eight of the case-control studies could only
meet the requirements for level 4 evidence.
Recent clinical trials suggest that anti-CCP is highly
accurate in selectively identifying RA patients [39, 89, 90],
and to be of particular diagnostic use in patients who are
negative for RF [90]. Current research appears to support
the hypothesis that RA patients who are positive or negative
for anti-CCP antibodies may constitute two subsets of the
RA syndrome with diﬀerent clinical presentations over time
[63]. As shown in Table 2, anti-CCP tests overall have
very high speciﬁcity but moderate levels of sensitivity; this
is in keeping with the hypothesis that diﬀerent patient
populations exist that are either anti-CCP positive or anti-
CCP negative (see Table 2). Synovial tissue from anti-
CCP+ patients expresses higher concentrations of immune
cytokines, has higher numbers of inﬁltrating lymphocytes,
and shows a greater degree of joint destruction than tissue
from anti-CCP-negative (anti-CPP−) patients [91]. Even
within anti-CCP+ patient populations, subgroups may be
diﬀerentiated by the quantity of serum antibodies recog-
nizing citrullinated peptides and speciﬁc anti-CCP isotypes
[67, 92].
A meta-analysis of 18 studies of anti-CCP found that the
pooled OR for development of RA related to a positive anti-
CCP2 test is 16.8, a strong indication of its diagnostic value
[93]. However, the absence of anti-CCP is diagnostically less
helpful,andinthecaseofapatientpresentingwithpersistent
peripheral joint swelling of four or more weeks duration,
a negative test should not be used as a reason not to refer.
Indeed, the poor negative predictive value is an argument to
discourage antibody testing in the primary care arena.
Until recently, established guidelines did not include
anti-CCPasarecommendedlaboratorytestforRAdiagnosis
[94, 95]. The absence of anti-CCP tests in RA guidelines
was largely due to the fact that current-generation anti-CCP
tests were developed within the past few years and that their
performance characteristics were still being studied in clini-
cal settings. However, in 2007 the European League Against
Rheumatism (EULAR) recommended that all patients diag-
nosed with early arthritis be tested for the presence of anti-
CCP [6], and the 2008 RA treatment guideline published
by the American College of Rheumatology (ACR) includes
positive anti-CCP as one of a number of measures of poor
patient prognosis to be used in treatment selection [96].
Over the past three years, the ACR and EULAR jointly
developed an updated set of criteria for RA to replace the
outdated 1987 ACR classiﬁcation criteria for RA. The new
2010 Rheumatoid Arthritis Classiﬁcation Criteria include
the presence of anticitrullinated protein antibodies as one
of the criteria to be used in determining whether or not
a patient should be diagnosed as having RA [97]. The
guidelines also mention that ACPAs are tested as anti-CCP
[97]. Table 3 provides a summary of the 2010 Rheumatoid
Arthritis Classiﬁcation Criteria.
3.6. Anti-CCP as a Diﬀerential Diagnostic Tool for RA. We
identiﬁed fourteen primary research articles that compared
anti-CCP test results in RA patients and in patients with
diseases that could be confounded with RA. Of these, the
vast majority (13 of 14) were case-control studies, while two
were cohort studies. Seven studies met the criteria for level
1 evidence, one study met the level 2, criteria and six of the
case-control studies met the level 4 criteria.
RA shares symptoms with other forms of arthritis as
well as with other disease conditions [1]. Diseases considered
as part of the diﬀerential diagnosis for RA include other
connective tissue diseases including systemic lupus erythe-
matosus and scleroderma, systemic diseases such as infective
endocarditis and rheumatic fever, spondyloarthropathiesAutoimmune Diseases 7
Table 3: 2010 ACR/EULAR scoring criteria for RA. The following table provides the scoring criteria for diﬀerent domains of evaluation. For
each cell in the table for which the patient satisﬁes the condition, the cell is scored by the number of points at the top of the column in which
it is found. The patient’s score is the sum of the scores for the individual cells. Patients with a total score of 6 or more points are diagnosed as
having RA.
Number of points 0 1 2 3 5
Joint involvement 1 medium-large joint 2–10 medium-large joints 1–3 small joints 4–10 small
joints
>10 small
joints
Serology Negative for both RF
and anti-CCP
Positive for either RF or
anti-CCP at low titer
(between 1x and 3x upper
l i m i to fn o r m a l )
Positive for either RF or
anti-CCP at high titer (>3x
upper limit of normal)
Duration of synovitis <6w e e k s ≥6w e e k s
Acute phase reactants normal CRP and ESR abnormal CRP or ESR
Source: [97].
including psoriatic arthritis, infectious arthritis, crystal-
induced arthritis or gout, endocrinopathies including thy-
roid disorders, soft tissue syndromes and degenerative dis-
orders such as ﬁbromyalgia and polyarticular osteoarthritis,
deposition disorders such as hemochromatosis, and malig-
nancies such as lung cancer and multiple myeloma [98].
Beyond serving as one of several criteria used in the
current classiﬁcation of RA [97], the results of anti-CCP
tests also may provide useful clinical information for the
diﬀerential diagnosis of RA [12]. Numerous studies have
compared anti-CCP levels in RA patients with control
groups comprised of mixed non-RA rheumatic diseases
(osteoarthritis, systemic lupus erythematosus (SLE), and
Sjogren syndrome (SS)), spondyloarthropathies (psoriatic
arthritis, ankylosing spondylitis), systemic sclerosis, crystal-
induced arthritis, gout, infectious arthritis, systemic scle-
rosis, ﬁbromyalgia, and/or other related conditions as well
as healthy controls [23, 24, 27, 42, 44–46, 51, 54, 72]. For
speciﬁcities in the range of 91.5% to 98.8%, anti-CCP tests
have shown sensitivities between 60.2% and 83.3% [23, 24,
27, 44–46, 51, 54, 72]. These results indicate that while not
suﬃcient for a diagnosis of RA as in the case of anti-CCP-
negative patients, the presence of elevated anti-CCP levels
c a nh e l ps u p p o r tt h ed i ﬀerential diagnosis of RA and the
above indications.
Two clinical studies comparing anti-CCP levels in the
sera of RA patients with levels measured in the sera of
smallsamplesofpatientswithotherarthriticconditionshave
foundanti-CCPantibodiestobeabsentintheseraofpatients
withosteoarthritis,polymyalgiarheumatica,crystalarthritis,
and postinfective polyarthritis [48, 99]. Although anti-CCP
antibodieshavebeenmeasuredintheserumofsomepatients
with hepatitis C, SLE, leprosy, juvenile idiopathic arthritis,
psoriatic arthritis, and SS, anti-CCP tests have been shown
to be able to diﬀerentiate RA from these other conditions
[15, 85, 99–104]. In patients who developed either RA or
other forms of arthritic disease including osteoarthritis, SLE,
spondyloarthropathy, neoplastic syndrome, and SS, Kudo-
Tanaka and colleagues found that serum anti-CCP levels in
the 18 RA patients were consistently >15U/mL, while that
of the 54 patients who developed non-RA arthropathies was
<15U/mL. The only exception was three patients diagnosed
with non-RA arthropathies but with pre-RA symptoms
whose serum anti-CCP levels were above 15U/mL [27].
Anti-CCP has also been shown to detect early RA in
patients with active tuberculosis [105]. For SLE patients
with chronic destructive/deforming arthritis and patients
with pulmonary tuberculosis who are anti-CCP positive, the
ratioofanti-CCPtounmodiﬁedarginine-containingpeptide
(CAP) diﬀers between these and RA patients, providing a
means for diﬀerential diagnosis [85, 106–108]. Interestingly,
in a study of patients with Down’s syndrome, over half of
the patients were positive for anti-CCP; however, none of the
patients had clinical signs of arthritis and there is currently
no known association between anti-CCP-positive sera in
Down’s patients and RA [101].
3.7. Anti-CCP as a Prognostic Tool for RA. We identiﬁed
seven primary research studies evaluating anti-CCP as a
prognostic tool for RA. All seven studies used a prospective
cohort design. Four studies met the criteria for level 1
evidence, two studies met the level 2 criteria, and one study
met the level 4 criteria.
Anti-CCP correlates with various aspects of RA and can
be a powerful predictor of disease course. The ESCISIT
recommends anti-CCP as one of several prognostic tools for
the identiﬁcation of patients with persistent and/or erosive
disease [6]. Several studies have demonstrated a strong
association between the presence of anti-CCP and joint
damage, with higher titers of anti-CCP antibodies in the
serum of patients with erosive RA [10, 47, 48, 50, 77, 109].
One study, however, failed to show a statistically signiﬁcant
relationship between anti-CCP and erosive disease [44]. In a
large,prospectivestudyofRApatientsfollowedover10years,
the presence of anti-CCP antibodies was the most robust
single predictor of radiographic progression in patients with
early RA. For these patients, even low or moderate levels of
anti-CCP antibodies resulted in an OR of 2.6 for the patient
developing radiographic progression, while for high levels
of anti-CCP antibodies, the OR reached 9.9 [110]. Other
studies have shown that anti-CCP is capable of predicting
patient development of erosive disease and hand deformity
[10, 12, 40, 90, 111, 112]. The presence of anti-CCP at
diagnosis is also capable of predicting higher levels of disease8 Autoimmune Diseases
activity as measured by the number of swollen joints, DAS28
and other clinical measures [113].
Studies have shown anti-CCP in combination with other
biomarkers can provide even greater prognostic power.
Serum anti-CCP antibodies in patients with the shared
epitope is associated with poorer radiological outcome [36].
Risk of severe disease was signiﬁcantly higher in anti-CCP+
patientswhocarryoneortwoHLA-DRB1alleleswithSE[85,
114]. Average expectancy rate for radiological progression
was 10 times higher in patients with the combined presence
of anti-CCP2 antibodies, RF, and SE, than in patients lacking
these three biomarkers [115, 116]. Grade of disease activity
was more accurately deﬁned by combination tests for the
presence of anti-CCP antibodies and alleles HLA-DR-B1∗04
with SE [115].
3.8. Rheumatoid Factor. RF, an antibody recognizing the Fc
or conserved portion of human antibodies [117], is present
in 60%–90% of RA patients with established RA [8, 118]b u t
in less than 50% of patients with early RA [118]. Three-to-
ﬁve percent of healthy adults have serum RF; this increases
to 10%–30% in the elderly [12, 119]. IgA, IgG, and IgM
forms of RF have all been identiﬁed in RA patients as well
as pan-speciﬁc and Ga-speciﬁc forms of IgM RF [34, 69,
120, 121]. The three isotypes appear at diﬀerent times pre-
clinically, with IgM-RF being present the furthest in advance
of diagnosis (3.8 years) followed by IgA-RF (3.2 years) and
I g GR F( 0 . 9y e a r s )[ 122].
RF is more established as a biomarker for RA than anti-
CCP, having been adopted as one of the ACR’s classiﬁcation
criteria for RA in 1987 [123]. The European Standing
Committee for International Clinical Studies Including
Therapeutics (ESCISIT) notes that it is one of several
prognostic markers used to identify patients with persistent
and/or erosive disease but does not recommend RF as a
diagnostic marker for RA [6] most likely at least in part
due to its limited speciﬁcity. RF is also common in other
autoimmune diseases, infectious diseases, and malignancies,
making it a relatively nonspeciﬁc marker of RA [3, 8].
Chronically high titers of RF are thought to be more speciﬁc
for RA [118] as well as being prognostic of poor outcomes
[94].
3.9. Anti-CCP and RF for Treatment Monitoring of RA.
The beneﬁt of anti-CCP tests for treatment monitoring is
controversial, with inconsistent ﬁndings on the extent and
duration of altered anti-CCP antibody levels following RA
treatments.Insomestudies,anti-CCPantibodylevelstended
to remain stable in RA patients following treatment or
decreased only slightly [79, 85, 124]. Other studies observed
signiﬁcant reductions in anti-CCP levels following treatment
only in patients whose disease duration was less than one
year [125, 126]. Signiﬁcant reductions in anti-CCP levels
have been reported in patients with established RA following
treatment with tissue necrosis factor (TNF) blockers and
in patient groups with positive clinical responses following
treatment with inﬂiximab, etanercept, and adalimumab [85,
124,125,127–130].However,severalstudieshaveshownthat
treatment of established RA patients with TNF-α inhibitors
reduces RF levels while having little or no eﬀect on anti-CCP
levels [17, 131–133]. These conﬂicting results may be due in
part to diﬀerences in subjects’ disease duration as well as the
length of followup [125].
Several studies have shown signiﬁcant diﬀerences in
treatment eﬀects on serum RF and anti-CCP antibody
levels. In studies showing reduced anti-CCP levels following
treatment, these reductions were smaller than reductions
seen in IgM-RF levels in patients with established RA [125].
RFlevelswereshowntobesigniﬁcantlyreducedbytreatment
with inﬂiximab with or without MTX [131–133], whereas
anti-CCP antibody levels were unaﬀected by treatment with
inﬂiximab [132, 133] and were only temporarily reduced
before returning to baseline levels by treatment with both
inﬂiximab and MTX [131]. Further, Mikuls et al. found
RF levels to decrease progressively in correlation with the
clinical course of disease, while anti-CCP levels decrease only
partially within the ﬁrst year of disease and in a manner that
correlatesneitherwithtreatmentnorwithclinicalcourse[17,
126]. Table 4 summarizes the ﬁndings from these studies.
These distinctions may yield information about diﬀeren-
tialeﬀectsoftreatmentinterventiononshort-andlong-lived
autoantibody-producing plasma cells at diﬀerent stages of
disease evolution or even according to treatment approach,
but they are unlikely to add value to standard clinical mea-
sures as a means to monitor therapeutic response. However,
in recently reported subanalysis of pooled data from two
phase III trials of the anti-CD20 biologic rituximab in RA,
patients who were seropositive for RF and/or anti-CPP, were
two-to-three times more likely to achieve ACR responses to
rituximab than those seronegative for both autoantibodies
[134], suggesting a potentially important role for both
biomarkers in treatment selection. These promising data
suggest the potential for personalized medicine approaches
using RA biomarkers to determine the most appropriate
treatments for RA patients.
3.10. Anti-CCP and RF in RA Pathology. Diagnostic and
prognostic studies comparing anti-CCP antibodies and RF
in the same RA patient samples suggest that the presence
or absence of these biomarkers in patient sera may deﬁne
patient subgroups with potentially diﬀerent outcomes (see
Table 5). Also, RAtreatment has signiﬁcantly diﬀerent eﬀects
on serum RF and anti-CCP antibody levels. These results
have led to the hypothesis that RF and anti-CCP are part
of two separate antibody systems representing diﬀerent but
overlapping physiological processes, with RF regulated by
TNF-α and anti-CCP independent of such regulation [17].
This hypothesis may be further corroborated by genetic
risk factor studies. Several RA susceptibility genes have been
identiﬁed, including HLA-DRB1 with the shared epitope
(SE) and PTPN22 [150, 151]. The combination of either
of these susceptibility genes with smoking appears to place
patients at signiﬁcantly higher risk of developing antibodies
against citrullinated proteins [150, 152–154]. Interestingly,
while HLA-DRB1 SE, PTPN22, and smoking were each
independent factors associated with the production ofAutoimmune Diseases 9
Table 4: Studies of anti-CCP and RF levels following treatment for RA.
Study Subjects Serum Tests Results
Alessandri et al.,
2004 [124]
Prospective cohort study of 43
patients with RA not
responding to DMARDs treated
with inﬂiximab in combination
with methotrexate
Serum samples collected and
tested for anti-CCP antibodies
and RF at baseline and after 24
weeks
(i) Serum titres of anti-CCP and RF decreased
signiﬁcantly after 24 weeks of treatment
(anti-CCP −14%; RF −20%)
(ii) Signiﬁcant decreases in serum anti-CCP
antibodies and RF observed only in patients with
clinical improvement
Atzeni et al.,
2006[128]
57 patients with RA not
responsive to methotrexate
treated with adalimumab as
part of the ReAct open-label
phase IIIb study
Serum samples collected and
tested for anti-CCP antibodies
and RF at baseline and after 24
and 48 weeks of followup
(i) Treatment resulted in signiﬁcant decreases in
anti-CCP serum levels at 24 weeks (−14%) and
48 weeks (−33%)
(ii) Treatment resulted in signiﬁcant decreases in
RF serum levels at 24 weeks (−33%) and 48 weeks
(−42%)
(iii) The decrease in anti-CCP and RF antibody
titers correlated with the clinical response to the
therapy
Bobbio-
Pallavicini et al.,
2004 [131]
Prospective study of 30
consecutive patients with RA;
patients were followed during
78 weeks of inﬂiximab and
methotrexate therapy for
refractory rheumatoid arthritis
Serum samples collected and
tested for anti-CCP antibodies
and RF at baseline and after 30,
54 and 78 weeks
(i) % patients positive for RF, Anti-CCP
approximately same at baseline and 78 weeks
(ii) Median RF titre underwent progressive
reduction from 128 IU/mL to 53IU/mL
(iii) Anti-CCP antibody titre signiﬁcantly
decreased at 30 weeks but returned to baselinev
Caramaschi et
al., 2005 [133]
Prospective cohort study of 27
patients with refractory RA
treated with inﬂiximab and
methotrexate
Serum samples collected and
tested for anti-CCP antibodies,
Rf and CRP at baseline and
after 22 weeks
(i) Serum levels of anti-CCP antibodies did not
change from baseline with inﬂiximab treatment
(ii) IgM RF and CRP levels decreased signiﬁcantly
with inﬂiximab treatment
Chen et al., 2006
[130]
90 patients with RA who failed
treatment with DMARDs;
randomized clinical protocol in
which all 90 patients continued
DMARD treatment and 52
patients were assigned for
additional treatment with
etanercept
Serum samples collected and
tested for anti-CCP and RFat
baseline and one month
intervals for three months
during the treatment course
(i) Serum anti-CCP levels decreased 31.3% in
patients positive for anti-CCP at baseline treated
with etanercept
(ii) Serum RF levels decreased 36% in patients
positive for RF at baseline treated with etanercept
(iii) Decreases in serum anti-CCP and RF levels
were progressive throughout the three-month
treatment course
(iv) Changes in anti-CCP levels was positively
correlated with changes in various clinical
measures of RA
De Rycke et al.,
2005 [132]
Prospective cohort study of 62
patients with refractory RA
treated with inﬂiximab
combined with methotrexate
Serum samples collected and
tested for anti-CCP antibodies,
I g MR F ,C R Pa n dE S Ra t
baseline and after 30 weeks
(i) RF titres signiﬁcantly reduced at baseline and
week 30 during inﬂiximab treatment
(ii) Anti-CCP antibodies unchanged by
inﬂiximab treatment
(iii) IgM RF titres correlated inversely with
changes in CRP and ESR; Anti-CCP antibodies
did not correlate inversely with these biomarkers
Mikuls et al.,
2004 [126]
Retrospective study of serum
samples from 66 RA patients
who completed double-blind,
randomized clinical protocols
(1) methotrexate,
hydroxychloroquine, and
sulfasalazine, (2) minocycline
versus placebo, and (3)
minocycline versus
hydroxychloroquine
Serum samples collected at
baseline and at a followup
averaging 13.7 months ± 8.6
months; Samples were stored at
−80◦ and later and tested for
anti-CCP antibodies and RF
(i) 52% of patients positive for anti-CCP
antibodies at baseline had >25% reduction in
anti-CCP antibody levels during treatment course
(ii) 55% of patients positive for RF at baseline had
>25% reduction in RF levels during treatment
course
(iii) Signiﬁcant reductions in anti-CCP levels was
only seen in patients with disease duration <12
months
(iv) No association was seen between reductions
in anti-CCP levels and treatment response
(v) Signiﬁcant reductions in RF levels were
determined by treatment response10 Autoimmune Diseases
Table 5: Characteristics of patients positive and negative for anti-CCP and rheumatoid factor.
Anti-CCP−/RF+ Anti-CCP+/RF+
(i) 5% [135]t o∼12%–20% [17, 136–139]o f R A
patients
(ii) 81% of RF+ patients [136]
(iii) Intermediate form of RA [135]
(i) 50% [136] to 63% [135] of RA patients
(ii) The probability of RA is ∼90%–100% [8, 17, 140]
(iii) High probability of developing erosive RA
[17, 140]
(iv) Most severe form of RA [135]
Anti-CCP−/RF− Anti-CCP+/RF−
(i) 14% [135]t o∼30% of RA patients [136]
(ii) A low probability of RA, but the disease cannot be
ruled out [8]
(iii) Mildest form of RA [135]
(i) 8% [136] to 18% [135] of RA patients
(ii) ∼20% [17, 141–145] to 40% RF-negative RA
patients [12, 146, 147]
(iii) Intermediate form of RA [135]
(iv) Substantial risk of developing RA [63, 148, 149]
antibodies against citrullinated proteins with an odds ratio
of 11.1, only HLA-DRB1 SE and smoking were independent
factors associated with the production of RF with a much
lower odds ratio of 4.4 [150], supporting the hypothesis that
these autoantibodies are produced by diﬀerent pathological
processes.
3.11. Anti-CCP and RF Test Performance. We identiﬁed
eight primary research articles that directly compared the
performance of anti-CCP and RF tests, half of which were
cohort studies, and the other half were case-control studies.
Six of the primary research studies met the criteria for level
1 evidence while two of the case-control studies satisﬁed the
criteria for level 4.
Historically, Anti-CCP has been viewed as highly speciﬁc
to RA but not as sensitive as RF. Pooled data from a meta-
analysis of over 5,000RA patients give RF a test sensitivity of
62% and a test speciﬁcity of 87% [93]. Studies have reported
the speciﬁcity of anti-CCP to be in the range of 95%-96%,
withasensitivityof53%–58%.[46,89,99].H owever ,ameta-
analysisof56studiesfoundthesensitivityofanti-CCP2tobe
68% with a speciﬁcity of 95%, suggesting that it may in fact
be more sensitive than RF [85, 90]. A similar analysis of 29
RF studies showed RF only to have a sensitivity of 60% with
a speciﬁcity of 79% [155, 156].
The absolute values of the two biomarkers’ sensitivities
and speciﬁcities range considerably across the studies iden-
tiﬁed by this paper. This is due, in part, to studies using
diﬀerent cutoﬀ values for anti-CCP and RF, and diﬀerent test
methodologies and manufacturers. In two studies, however,
cutoﬀ values corresponding to a predeﬁned test speciﬁcity
of >98.5% were applied to serum tests of both biomarkers,
allowing for a head-to-head comparison of sensitivities for
anti-CCP and RF. The resulting sensitivities were 73.7%–
77.7% for anti-CCP but only 7.4%–12.8% for RF [36, 111].
In a more recent study, Wild et al. found similar results when
the cutoﬀ value was set at 95% speciﬁcity, with anti-CCP
identifying 77% of RA patients while RF identiﬁed only 62%
[157]. Thus, anti-CCP appears to have better sensitivity and
speciﬁcity than RF. A meta-analysis also showed anti-CCP
to have higher odds ratios for the prediction of developing
RA and for radiographic progression than RF, indicating that
anti-CCP may be the better prognostic tool [93].
However, this does not mean that anti-CCP can replace
RF in diagnostic and prognostic testing for RA. Of RF-
patients, approximately 20% are anti-CCP+ [17, 158–161].
Of anti-CCP-patients, a comparable 15%–20% are RF-
positive [17, 162–164]. Approximately 30% of RA patients
are reported to be negative for both anti-CCP and RF
[136]. The two tests therefore appear to be complementary,
with anti-CCP of particular diagnostic value for RF-patients
[79, 109]. In combination, the two tests appear to be even
more powerful [109] with a positive predictive value (PPV)
nearing 100%, greater than the PPV of either of the tests
alone [17, 99, 165]. The presence of both RF and anti-CCP
antibodies has also been shown to predict which patients
will develop RA [17, 166, 167]. Interestingly, Shovman et
al. found the highest correlation of serum RF and anti-
CCP in nonerosive patients; however, the reason for this
correlation is not clear [50]. Improved diagnostic results for
the combination of anti-CCP and RF have been shown when
RF is measured using a multiplex cytoﬂuorimetric assay
[168]. Table 5 summarizes characteristics of patients positive
and negative for anti-CCP and RF.
3.12. Prediction Algorithms for RA in Development. Given the
limitations of individual tests to predict RA development
and disease progression, predictive algorithms are being
developed that combine relevant patient demographics with
various test measures, including combinations of serum
biomarkers. Biomarker combinations that show promise as
future diagnostic or prognostic panels for early RA include
anti-CCP,anti-MCV,andIgM-RF[66],anti-CCPandmatrix
metalloproteinases 3 (MMP-3) [169], and anti-CCP, MMP-
3 and high-sensitivity CRP (hsCRP) [170]. Elevated anti-
CCP, MMP-3 and hsCRP were all seen preclinically [170].
The combination of anti-CCP, RF and CRP was observed
to predict development of RA [31]; however, another study
showed anti-CCP by itself to be superior in predicting
RA development over any combinations with RF, CRP,
MMP-3, and antigalactosyl IgG antibody (CARF) [27]. The
combination of anti-CCP or other anticitrullinated protein
antibodies with RF and sE-selectin also has shown both
diagnostic and prognostic potential [171].Autoimmune Diseases 11
4. Discussion
RF tests are well established as diagnostic and prognostic
tools for RA and have been incorporated as a criterion in
the ACR’s classiﬁcation of RA patients since 1987 [123].
The recent addition of ACPA testing in the ACR’s updated
2010 RA classiﬁcation criteria is an acknowledgment of
the clinical value of these biomarkers for the diagnosis
of RA patients [97]. Alone, RF and anti-CCP tests are
not suﬃcient for the diagnosis of RA, since not all RA
patients have both biomarkers and some patients lack both
(see Table 5). However, in combination with other clinical
measures, the two biomarkers together provide important
diagnostic and prognostic information about diﬀerent RA
patient populations depending on which of the biomarkers
if any are present in patient sera (see Tables 3 and 5).
Anti-CCP tests have evolved signiﬁcantly over the past
20 years. From the initial linear antigens used to identify
serum autoantibodies against citrullinated proteins, the
development and reﬁnement of cyclic citrullinated antigens
has led to improvements in test sensitivity while maintaining
extremely high levels of speciﬁcity [17, 22]. Anti-CCP tests
have been shown to be both more sensitive and more speciﬁc
a test for RA than RF [36, 85, 90, 93, 111, 155, 156].
This paper identiﬁes a large number of diagnostic studies
providing level 1 evidence of the clinical value of anti-
CCP tests in the diagnosis of RA supporting the validity
of anti-CCP tests for this application. Fewer studies were
reviewed that evaluated the prognostic value of anti-CCP
tests and these provided mixed levels of evidence. Given the
promising results to date that anti-CCP is indicative of more
severe disease courses, it would be beneﬁcial for additional
prospective, longitudinal studies with good patient followup
to be conducted to further validate the prognostic value of
anti-CCP tests.
Three generations of anti-CCP tests are currently avail-
able commercially. Of the three generations, the second
generation tests currently appear to provide the best per-
formance [24, 35, 56, 59–64]. Given diﬀerent cutoﬀ levels,
sensitivities and speciﬁcities, there has been a growing
recognition that anti-CCP results are not interchangeable
across laboratories [35, 63, 74]. The ongoing development
of international reference standards is a critical element in
eﬀorts to harmonize anti-CCP test results in order to make
the interpretation of these results consistent and improve the
ability of clinicians to make patient management decisions
[63, 74].
In conclusion, Anti-CCP and RF are recognized
biomarkers associated with RA that are incorporated in
the current ACR classiﬁcation guidance for RA diagnosis.
The studies reviewed indicate that the two biomarkers are
promising early diagnostic tests with the potential to support
early, aggressive intervention using newer RA treatment
options (see Figure 1). Anti-CCP appears to be a strong
predictor of erosive RA, making it a potentially important
prognostictoolthatcouldbeusedtoinformpatientmanage-
ment decisions. Additional prospective longitudinal research
studies of the prognostic value of anti-CCP tests would help
to validate this clinical application. Finally, the adoption of
international reference standards will signiﬁcantly improve
the consistency of anti-CCP results across laboratories.
Learning Points
(i) The preclinical presence of anti-CCP and RF makes
these important biomarkers for early RA.
(ii) Newer-generation anti-CCP assays provide higher
sensitivity and speciﬁcity than RF.
(iii) At comparable speciﬁcity, the sensitivities of anti-
CCP2 tests are superior to those of anti-CCP1 tests
and equal to or better than those of anti-CCP3 tests.
(iv) Anti-CCP and RF levels may reﬂect diﬀerent patho-
logical pathways in RA and, in combination, can
identify the majority of patients with RA.
(v) The absence of anti-CCP is diagnostically less helpful
in a patient presenting with persistent peripheral
joint swelling.
(vi) ∼50% of new-onset RA patients (fulﬁlling ACR
criteria by 18/12 follow up) are anti-CCP positive
[84].
(vii) Early treatment of anti-CCP positive UA (not ful-
ﬁlling ACR criteria for RA) with MTX slows devel-
opment of both full-blown RA and joint damage
(PROMPT STUDY) [4].
(viii) Recent ﬁndings suggest that patients positive for
anti-CCP and/or RF will respond better to anti-
CD20 therapeutics than patients seronegative for
both autoantibodies.
(ix) Anti-CCP positivity is an important predictor of
radiographic progression in RA patients.
Key Messages
(i) Anti-CCP preclinical presence makes it an important
biomarker for early RA.
(ii) Newer generation anti-CCP assays oﬀer high speci-
ﬁcity, and combined with RF tests, greater sensitivity.
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